Michael is a senior drug development professional with more than 20 years’ experience in the life sciences industry. He has served in senior leadership positions across disciplines including clinical and preclinical drug development, project & portfolio management, regulatory affairs and metabolism research.
“Translating outstanding science into therapies for patients is my passion. At Cellestia, we have developed a targeted cancer drug with a new mode of action that is well tolerated and we know it works! Now our focus is to provide hope by bringing this medicine to patients who currently have no treatment options.”
He has many years of experience in leading global development projects, covering the full range of drug development, from early stage preclinical through Phase I, II and III clinical development, including IND and NDA submissions.
Most recent assignments were with Novartis Pharma AG, Translational Medicine Oncology, working as Senior Global Program Manager and Polyphor Ltd., where he served as Head of Clinical and Preclinical Development. Under his leadership, several new oncology drugs were brought into clinical development and reached clinical proof of concept.
Michael holds a PhD in Biotechnology and an MSc in Chemistry.